Coralie Foschia, MSc

Experience

• 

  Proteaxis

  Feb 2004 - Feb 2005

  Responsable Business Développement
• 

  Genzyme

  Mar 2006 - Feb 2014

  Responsable Regional ( MSL)

  Gaucher Disease [Beta Glucocerebrosidase], Fabry Disease[Alpha-Galactosidase], Mucopolysaccharidosis I [Alpha-L-Iduronydase], Pompe Disease [Alpha-Glucosidase], Familial Hypercholesterolemia [Mipomersen]2011-2012 : Pre-launch ASO Mipomersen - No EMA approval2009-2014: Responsible for the local strategy elaborationandn execution. key opinion leader identification and management.=>Profiling, implementation, coordination of national clinical research protocols - crafted-hoc protocol to shorten patient diagnostic journey in collaboration with expert centres.=>Monitoring and analysis of relevant scientific literature and create high value content to be presented to healthcare professionals. Supported medical publications.2006-2009 : French East Indies [Guadeloupe, Martinique,French Guyana]Development of the French West Indies territories for all Genzyme rare disease portfolio. Myozyme PreLaunch and early access. Show less

• 

  Synageva BioPharma Corp.

  Mar 2014 - May 2016

  Medical Science Liaison Pre-Launch

  Synageva acquired by Alexion Dec 2015. Lipase Acid Deficiency[LAL-D Kana] & Hypophosphatasia [ Strensiq]=>Profiled and build relationships with key opinion leaders, French and European scientific communities (Lipidology, Hepatology, Pediatric, Cardiology)=>Created, localised, delivered high value scientific/medical content and data to educate healthcare professionals [Disease Awareness, Clinical Data via Symposia, Adboards]=>Identify experts center to implement and monitor clinical trials, Registries, clinical prevalence studies=>Develop in partnership with experts clinicians original research screening protocols in diverse patients' cohorts - EAP implementation Show less

• 

  Biogen

  May 2016 - Feb 2024

  Ensuring appropriate resourcing, skills and capabilities are in place to support affiliates with Regional/Global medical plans, clinical activities implementation and business support. Real World Data Generation, Medical Education, Scientific Communication, Congresses, Field Medical Excellence. Intercontinental Region covering 22 countries including CHINA, Japan, Australia, Brazil, Gulf Countries.=> Elaborate and implemented Regional medical plan integrating affiliates needs. Tailored and led Medical Education deliverables for local use to increase knowledge, improve patient care and treatment differentiation. [20 easy plug-in Initiatives: webinars, symposium and standalone, advisory boards content. Organization of 2 live standalone with >150 clinicians from over 15 countries.=>Served as subject expert matter in scientific, strategic and tactical discussions and representations. Internally with cross-functional teams.[braced reimbursement extension in the region not limited to CHINA, Japan, Brazil, Australia]. Externally with key opinion leader management.=> Supported with Global Medical workstream optimisation [Insights,Monthly synerrgies with clinical development teams, Scientific exchange forum within medical and R&D, maintaining state of art knowledge. Field medical excellence collaboration with strategic account planning and key opinion leader engagement plans, differentiation trainings development.Reviewed Regional /local real world evidence study proposal. Provided input, guided on execution, timeline and budgets.[supported global team to develop or extrapolate scientific hypothesis and define tactics serving strategic imperatives and community] Show less =>Expanding Access : Led initiatives to broaden the availability of Nusinersen in Australia, opening patient access to adults and pre-symptomatic patients. Kicked off early access program in New Zealand ensuring timely patient treatment ahead of formal market approval.=>Developed and enhanced partnerships :with top neuromuscular experts across the region, establishing Biogen as a trusted partner in the neuromuscular field (Data Dissemination, National Standalone, Adboards, Scientific Webinars). This role involved nurturing enduring relationships, developed rising stars, scientific projects collaboration.(Registries AU & NZ, Virtual Reality Project)=>Leadership and Regional Development : Elevated the Australian affiliate to a leadership position within Asia Pacific region by leveraging its strategic position and expertise in neuromuscular diseases (SMA/ ALS). Contributed to regional integration and fostered cohesive growth by providing strategic guidance and promoting value-driven initiatives. (Medical Educations content and events, Field Medical Excellence standards setting, Regional Congresses with international speakers) Show less Started as unique medical referent for nusinersen pre-launch in France, Belgium and Netherlands. One year before EMA approval. Strong collaboration with Global and European Team. Preparing the Neuromuscular scientific communities : Healthcare Professionals, Patient association groups for the 1st Antisense Oligonucleotide Therapy (ASO).=>Responsible for center readiness, profiling key opinion leaders, networks, scientific societies, patient advocacy associations and initiated foundational relationships. Placing Biogen as a trusted partner in rare diseases and SMA. [From 1 clinical trial center to 45 centres open]=> implemented early access [1st patient in Europe enrolled in France Oct 2016, 2nd in Europe with total patient enrolled]=>Developed medical education initiatives and disseminated high quality and complex scientific data to treatment sites, national congresses, advisory boards, national SMA standalone.[ Intrathecal Injection Academy]=>Created a trustful environment with key opinion leaders fostering research collaboration. Developing concepts and protocols in partnership. (French SMA Registry, Biomarker identification, patient management improvement.=>Supported localisation or development and review of all key documents, clinical study reports, Investigator documents, EAP brochures, Regulatory authorities briefing book, reimbursment dossier, safety updates reports, medical inquiries, market outlook documents... Show less

  • Associate Director - Neuromuscular Diseases Lead - Intercontinental Region

    Jun 2021 - Feb 2024

  • Medical Liaison Manager

    Jul 2018 - Jun 2021

  • Medical Science Liaison Pre Launch - Spinal Muscular Atrophy (SMA) - France/Belgique

    May 2016 - Jul 2018